Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial.
Silverman MH, Strand V, Markovits D, Nahir M, Reitblat T, Molad Y, Rosner I, Rozenbaum M, Mader R, Adawi M, Caspi D, Tishler M, Langevitz P, Rubinow A, Friedman J, Green L, Tanay A, Ochaion A, Cohen S, Kerns WD, Cohn I, Fishman-Furman S, Farbstein M, Yehuda SB, Fishman P.
Silverman MH, et al. Among authors: fishman p, fishman furman s.
J Rheumatol. 2008 Jan;35(1):41-8. Epub 2007 Nov 15.
J Rheumatol. 2008.
PMID: 18050382
Clinical Trial.